These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 884924)

  • 1. Bilary disposition of adriamycin.
    Riggs CE; Benjamin RS; Serpick AA; Bachur NR
    Clin Pharmacol Ther; 1977 Aug; 22(2):234-41. PubMed ID: 884924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
    Benjamin RS; Riggs CE; Bachur NR
    Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.
    Hartman N; Basseches PJ; Powis G
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):11-5. PubMed ID: 6819097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
    Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
    Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].
    Ehninger G; Stocker HJ; Proksch B; Wilms K
    Klin Wochenschr; 1980 Sep; 58(18):927-34. PubMed ID: 7206588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model.
    Behnia K; Boroujerdi M
    Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
    Cummings J; Milstead R; Cunningham D; Kaye S
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
    Leca F; Marchiset-Leca D; Noble A; Antonetti M
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile secretory function: a determinant of adriamycin disposition.
    Tavoloni N; Guarino AM
    Arch Int Pharmacodyn Ther; 1980 Jun; 245(2):180-97. PubMed ID: 7406604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and metabolism of adriamycin in the rat.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 21(4):244-55. PubMed ID: 7422708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
    Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
    Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
    Sweatman TW; Israel M
    Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
    Israel M; Wilkinson PM; Pegg WJ; Frei E
    Cancer Res; 1978 Feb; 38(2):365-70. PubMed ID: 620407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.
    Andrews PA; Brenner DE; Chou FT; Kubo H; Bachur NR
    Drug Metab Dispos; 1980; 8(3):152-6. PubMed ID: 6104578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biliary and urinary excretion of adriamycin in anesthetized rats.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 20(5):256-67. PubMed ID: 7393994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time dependency of adriamycin and adriamycinol kinetics.
    Gil P; Favre R; Durand A; Iliadis A; Cano JP; Carcassonne Y
    Cancer Chemother Pharmacol; 1983; 10(2):120-4. PubMed ID: 6831625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.
    Iguchi H; Tone H; Ishikura T; Takeuchi T; Umezawa H
    Cancer Chemother Pharmacol; 1985; 15(2):132-40. PubMed ID: 4017162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
    Chlebowski RT; Chan KK; Tong MJ; Weiner JM; Ryden VM; Bateman JR
    Cancer; 1981 Sep; 48(5):1088-95. PubMed ID: 6268277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.